Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics, Inc. reported equity compensation and related share movements for Chief Scientific Officer Paige Mahaney. On February 13, 2026, Mahaney received a grant of 240,000 restricted stock units (RSUs). Of these, 120,000 RSUs will vest in three equal annual installments starting on February 13, 2027, and 120,000 RSUs will vest in full on February 13, 2029, with the latter portion subject to performance milestones.
On February 14, 2026, Mahaney acquired 7,050 shares of common stock upon vesting of a previously disclosed RSU grant, and 2,446 shares were withheld by the company to cover tax obligations, which the filing states does not represent a sale. After these transactions, Mahaney directly owned 336,910 shares of common stock.
C4 Therapeutics Chief People Officer Kelly Schick reported several equity compensation transactions in Common Stock. Schick received a grant of 200,000 restricted stock units, with 100,000 vesting in three equal annual installments starting on February 13, 2027 and 100,000 vesting in full on February 13, 2029, subject to performance milestones. Additional shares were acquired through the vesting of previously granted RSUs and by exercising derivative securities, while 7,269 and 1,735 shares were withheld to cover tax obligations, which the company notes do not represent market sales. Following these transactions, Schick directly owned 299,881 shares of Common Stock.
C4 Therapeutics, Inc. reported multiple equity transactions by President & CEO Andrew Hirsch. On February 13, 2026, he received 700,000 restricted stock units (RSUs). According to the disclosure, 350,000 RSUs vest in three equal annual installments beginning on February 13, 2027, and 350,000 RSUs vest in full on February 13, 2029, subject to potential acceleration if certain performance milestones are achieved.
On February 14 and 15, 2026, previously granted RSUs vested, resulting in acquisitions of common stock through derivative exercises and conversions. In connection with these vestings, the company withheld 39,154 and 9,057 shares of common stock at $1.89 per share to cover tax withholding obligations. The filing states these withheld shares do not represent sales by Hirsch. After these transactions, he continued to hold over one million shares directly.
C4 Therapeutics Chief Medical Officer Leonard Reyno reported multiple equity compensation transactions in company stock. On February 13, 2026, he received a grant of 240,000 restricted stock units (RSUs), with 120,000 RSUs vesting in three equal annual installments starting on February 13, 2027, and 120,000 RSUs vesting in full on February 13, 2029, subject to potential performance-based acceleration.
On February 14, 2026, previously disclosed RSU awards vested, resulting in the acquisition of 30,950 shares of common stock at no cost. On the same date, 16,579 shares were withheld by the company at $1.89 per share to cover tax obligations related to the RSU vesting, which the filing states does not represent a sale. Following these transactions, Reyno directly owned 379,803 shares of common stock.
C4 Therapeutics, Inc. reported insider equity activity by Chief Financial Officer Kendra Adams. She received a grant of 240,000 restricted stock units (RSUs), which vest in stages through February 13, 2029, based on time and performance conditions.
Adams also acquired 30,950 and 3,750 shares of common stock through vesting and exercise of previously granted RSUs, and 15,381 and 1,863 shares were withheld by the company at $1.89 per share to cover tax obligations. After these transactions, she directly holds 385,098 shares of common stock.
C4 Therapeutics Chief Accounting Officer Mark Mossler reported equity compensation and related share movements. He received a grant of 56,980 restricted stock units, each representing one future share of common stock upon vesting and settlement.
According to the grant terms, 28,490 RSUs vest in three equal annual installments starting on February 13, 2027, and 28,490 RSUs vest in full on February 13, 2029, subject to performance milestones. Separately, 9,420 shares of common stock were acquired upon vesting of previously disclosed RSU awards, while 3,268 shares were withheld by the company at a price of $1.89 per share to cover tax obligations, which the filing specifies is not a sale. After these transactions, Mossler directly holds 71,916 shares of common stock.
C4 Therapeutics, Inc. received an amended Schedule 13G/A showing updated ownership by OrbiMed entities. OrbiMed Advisors LLC reports beneficial ownership of 521,368 shares of common stock, representing 0.5% of the class. OrbiMed Capital LLC reports 883,534 shares, or 1.0% of the class.
Together, the reporting persons hold 1.5% of C4 Therapeutics’ common stock on behalf of other persons who have rights to dividends or sale proceeds. Investment and voting power is exercised through a management committee, whose individual members disclaim beneficial ownership. The securities are described as acquired and held in the ordinary course of business, not to influence control.
Lynx1 Capital Management LP and Weston Nichols report a 7.3% beneficial stake in C4 Therapeutics, Inc. common stock, totaling 7,098,133 shares. This percentage is based on 96,914,418 shares outstanding as of October 29, 2025, from the company’s Form 10‑Q for the quarter ended September 30, 2025.
The shares are directly held by Lynx1 Master Fund LP, which has the right to receive dividends and sale proceeds, while Lynx1 Capital Management LP serves as investment manager and Weston Nichols is its control person. The reporting parties certify the holdings were not acquired to change or influence control of C4 Therapeutics.
C4 Therapeutics, Inc. shareholder update: a group of Soleus investment entities filed an amended Schedule 13G/A reporting passive ownership of C4 Therapeutics common stock.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 10,334,114 shares, representing 9.99% of the outstanding common stock based on 96,914,418 shares as of October 29, 2025. This total includes warrants to purchase up to 6,530,172 shares, subject to beneficial ownership limitations in those warrants. Other Soleus entities, including Soleus Private Equity Fund III, L.P., report 6,072,822 shares, or 5.9% of the class, including warrants to purchase up to 5,822,829 shares.
The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of C4 Therapeutics, and multiple Soleus entities and Guy Levy disclaim beneficial ownership beyond Section 13(d) reporting obligations.
Morgan Stanley and Morgan Stanley & Co. LLC report a significant passive stake in C4 Therapeutics, Inc. common stock. They beneficially own 8,974,191 shares, representing 9.3% of the class as of 12/31/2025, with all voting and dispositive power held on a shared basis.
The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of C4 Therapeutics.